Literature DB >> 23365101

Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database.

Günther Metz1, Nicholas Coppard, Jonathon M Cooper, Martin B Delatycki, Alexandra Dürr, Nicholas A Di Prospero, Paola Giunti, David R Lynch, J B Schulz, Christian Rummey, Thomas Meier.   

Abstract

The aim of this cross-sectional study was to analyse disease progression in Friedreich's ataxia as measured by the International Cooperative Ataxia Rating Scale. Single ratings from 603 patients with Friedreich's ataxia were analysed as a function of disease duration, age of onset and GAA repeat lengths. The relative contribution of items and subscales to the total score was studied as a function of disease progression. In addition, the scaling properties were assessed using standard statistical measures. Average total scale progression per year depends on the age of disease onset, the time since diagnosis and the GAA repeat length. The age of onset inversely correlates with increased GAA repeat length. For patients with an age of onset ≤14 years associated with a longer repeat length, the average yearly rate of decline was 2.5 ± 0.18 points in the total International Cooperative Ataxia Rating Scale for the first 20 years of disease duration, whereas patients with a later onset progress more slowly (1.8 ± 0.27 points/year). Ceiling effects in posture, gait and lower limb scale items lead to a reduced sensitivity of the scale in the severely affected population with a total score of >60 points. Psychometric scaling analysis shows generally favourable properties for the total scale, but the subscale grouping could be improved. This cross-sectional study provides a detailed characterization of the International Cooperative Ataxia Rating Scale. The analysis further provides rates of change separated for patients with early and late disease onset, which is driven by the GAA repeat length. Differences in the subscale dynamics merit consideration in the design of future clinical trials applying this scale as a neurological assessment instrument in Friedreich's ataxia.

Entities:  

Mesh:

Year:  2013        PMID: 23365101      PMCID: PMC3624678          DOI: 10.1093/brain/aws309

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  18 in total

1.  International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia?

Authors:  Stefan J Cano; Jeremy C Hobart; Paul E Hart; L V Prasad Korlipara; Anthony H V Schapira; J Mark Cooper
Journal:  Mov Disord       Date:  2005-12       Impact factor: 10.338

2.  Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale.

Authors:  S H Subramony; W May; D Lynch; C Gomez; K Fischbeck; M Hallett; P Taylor; R Wilson; T Ashizawa
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

3.  The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms.

Authors:  Frank Weidemann; Christian Rummey; Bart Bijnens; Stefan Störk; Ruta Jasaityte; Jan Dhooge; Aigul Baltabaeva; George Sutherland; Jörg B Schulz; Thomas Meier
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

4.  How is disease progress in Friedreich's ataxia best measured? A study of four rating scales.

Authors:  M C Fahey; L Corben; V Collins; A J Churchyard; M B Delatycki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10-20       Impact factor: 10.154

5.  Reliability and validity of the International Cooperative Ataxia Rating Scale: a study in 156 spinocerebellar ataxia patients.

Authors:  Tanja Schmitz-Hübsch; Sophie Tezenas du Montcel; Laszlo Baliko; Sylvia Boesch; Sara Bonato; Roberto Fancellu; Paola Giunti; Christoph Globas; Jun-Suk Kang; Berry Kremer; Caterina Mariotti; Bela Melegh; Maryla Rakowicz; Rafal Rola; Sylvie Romano; Lodger Schöls; Sandra Szymanski; Bart P C van de Warrenburg; Elzbieta Zdzienicka; Alexandra Dürr; Thomas Klockgether
Journal:  Mov Disord       Date:  2006-05       Impact factor: 10.338

6.  Friedreich's ataxia. Revision of the phenotype according to molecular genetics.

Authors:  L Schöls; G Amoiridis; H Przuntek; G Frank; J T Epplen; C Epplen
Journal:  Brain       Date:  1997-12       Impact factor: 13.501

7.  International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology.

Authors:  P Trouillas; T Takayanagi; M Hallett; R D Currier; S H Subramony; K Wessel; A Bryer; H C Diener; S Massaquoi; C M Gomez; P Coutinho; M Ben Hamida; G Campanella; A Filla; L Schut; D Timann; J Honnorat; N Nighoghossian; B Manyam
Journal:  J Neurol Sci       Date:  1997-02-12       Impact factor: 3.181

8.  Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia.

Authors:  A O Hausse; Y Aggoun; D Bonnet; D Sidi; A Munnich; A Rötig; P Rustin
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

9.  Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.

Authors:  Nicholas A Di Prospero; Angela Baker; Neal Jeffries; Kenneth H Fischbeck
Journal:  Lancet Neurol       Date:  2007-10       Impact factor: 44.182

10.  Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.

Authors:  Pascale Ribaï; Françoise Pousset; Marie-Laure Tanguy; Sophie Rivaud-Pechoux; Isabelle Le Ber; Franchesca Gasparini; Perrine Charles; Anne-Sophie Béraud; Michele Schmitt; Michel Koenig; Alain Mallet; Alexis Brice; Alexandra Dürr
Journal:  Arch Neurol       Date:  2007-04
View more
  17 in total

1.  An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.

Authors:  Eppie M Yiu; Geneieve Tai; Roger E Peverill; Katherine J Lee; Kevin D Croft; Trevor A Mori; Barbara Scheiber-Mojdehkar; Brigitte Sturm; Monika Praschberger; Adam P Vogel; Gary Rance; Sarah E M Stephenson; Joseph P Sarsero; Creina Stockley; Chung-Yung J Lee; Andrew Churchyard; Marguerite V Evans-Galea; Monique M Ryan; Paul J Lockhart; Louise A Corben; Martin B Delatycki
Journal:  J Neurol       Date:  2015-04-07       Impact factor: 4.849

2.  Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length.

Authors:  Yogesh K Chutake; Christina Lam; Whitney N Costello; Michael Anderson; Sanjay I Bidichandani
Journal:  Ann Neurol       Date:  2014-08-30       Impact factor: 10.422

3.  Inducible and reversible phenotypes in a novel mouse model of Friedreich's Ataxia.

Authors:  Vijayendran Chandran; Kun Gao; Vivek Swarup; Revital Versano; Hongmei Dong; Maria C Jordan; Daniel H Geschwind
Journal:  Elife       Date:  2017-12-19       Impact factor: 8.140

4.  Translating HDAC inhibitors in Friedreich's ataxia.

Authors:  Elisabetta Soragni; Joel M Gottesfeld
Journal:  Expert Opin Orphan Drugs       Date:  2016-07-31       Impact factor: 0.694

5.  Natural History of Friedreich's Ataxia: Heterogeneity of Neurological Progression and Consequences for Clinical Trial Design.

Authors:  Christian Rummey; Louise A Corben; Martin Delatycki; George Wilmot; Sub H Subramony; Manuela Corti; Khalaf Bushara; Antoine Duquette; Christopher Gomez; J Chad Hoyle; Richard Roxburgh; Lauren Seeberger; Grace Yoon; Katherine Mathews; Theresa Zesiewicz; Susan Perlman; David R Lynch
Journal:  Neurology       Date:  2022-07-11       Impact factor: 11.800

6.  Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort.

Authors:  Christian Rummey; John M Flynn; Louise A Corben; Martin B Delatycki; George Wilmot; Sub H Subramony; Khalaf Bushara; Antoine Duquette; Christopher M Gomez; J Chad Hoyle; Richard Roxburgh; Lauren Seeberger; Grace Yoon; Katherine D Mathews; Theresa Zesiewicz; Susan Perlman; David R Lynch
Journal:  Ann Clin Transl Neurol       Date:  2021-05-05       Impact factor: 4.511

7.  FXN Promoter Silencing in the Humanized Mouse Model of Friedreich Ataxia.

Authors:  Yogesh K Chutake; Whitney N Costello; Christina C Lam; Aniruddha C Parikh; Tamara T Hughes; Michael G Michalopulos; Mark A Pook; Sanjay I Bidichandani
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

8.  Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor.

Authors:  Yogesh K Chutake; Christina C Lam; Whitney N Costello; Michael P Anderson; Sanjay I Bidichandani
Journal:  Nucleic Acids Res       Date:  2016-02-20       Impact factor: 16.971

9.  Stratification of disease progression in a broad spectrum of degenerative cerebellar ataxias with a clustering method using MRI-based atrophy rates of brain structures.

Authors:  Rie Sasaki; Futaba Maki; Daisuke Hara; Shigeaki Tanaka; Yasuhiro Hasegawa
Journal:  Cerebellum Ataxias       Date:  2017-06-29

10.  Analyzing the Effects of a G137V Mutation in the FXN Gene.

Authors:  Nathalie Faggianelli; Rita Puglisi; Liana Veneziano; Silvia Romano; Marina Frontali; Tommaso Vannocci; Silvia Fortuni; Roberto Testi; Annalisa Pastore
Journal:  Front Mol Neurosci       Date:  2015-11-25       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.